Kalvista Pharmaceuticals, Inc. (KALV)

Last Year

22-Nov-23 -- 21-Nov-24

Time Period:

$12.70M Net Amount

Buy:	$13.58M	$11.97 - $14.22
Sell:	($881.27K)	$12.02 - $13.03

Company Sentiment

Drugs - Generic

Drugs

Insider Trading Sentiment: Strong Buy

Sentiment Breakdown by Insider

1

(3)

0

(2)

0

(1)

12

0

4

+1

0

+2

1

+3

Two Year Chart

22-Nov-22 -- 21-Nov-24

Price ($)

Two Year Stock Price Chart

Sentiment

Buy & Sell Volume ($)

Two Year Insider Trading Volume Chart

Recent Insider Trades

Last Transaction		Last Three Months
SEC Filing	Transaction	Insider	Sentiment	Company	Holdings Change	Buy Amount	Sell Amount	Buy Price Range	Sell Price Range
19-Nov-24 7:18 PM View:	18-Nov-24 Option Sale ($66.57K)	Yea Christopher Chief Development Officer		Kalvista Pharmaceuticals, Inc. - KALV	95% 46.05K to 89.98K	0	0	--	--	Show Txns Hide Txns

21-May-24 5:59 PM View:	20-May-24 Option Sale ($95.15K)	Feener Edward P. Chief Scientific Officer		Kalvista Pharmaceuticals, Inc. - KALV	(9%) 79.83K to 72.86K	0	($520.81K) (50%)	--	$13.00 - $13.03	Show Txns Hide Txns

21-Feb-24 9:41 PM View:	20-Feb-24 Option Sale ($351.29K)	Crockett Thomas Andrew CEO Director		Kalvista Pharmaceuticals, Inc. - KALV	34% 157.53K to 211.2K	0	($360.45K) (19%)	--	$12.02	Show Txns Hide Txns

19-Nov-24 7:18 PM View:	18-Nov-24 Option Sale ($74.77K)	Audhya Paul K. Chief Medical Officer		Kalvista Pharmaceuticals, Inc. - KALV	158% 36.57K to 94.2K	0	0	--	--	Show Txns Hide Txns

08-Feb-24 8:11 PM View:	08-Feb-24 Purchase $437.28K	Venrock Healthcare Capital ... 10% Owner		Kalvista Pharmaceuticals, Inc. - KALV	35% 3.57M to 4.82M	$13.58M 30%	0	$11.97 - $14.22	--	Show Txns Hide Txns

19-Nov-24 7:19 PM View:	18-Nov-24 Option Sale ($133.29K)	Palleiko Ben CHIEF EXECUTIVE OFFICER Director		Kalvista Pharmaceuticals, Inc. - KALV	137% 112.44K to 266.6K	0	0	--	--	Show Txns Hide Txns